cMyc Cancer Research Results

cMyc, cellular-MYC oncogene: Click to Expand ⟱
Source:
Type: oncogene
The MYC proto-oncogenes are among the most commonly activated proteins in human cancer. The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell. The c-Myc oncogene is a ‘master regulator’ of both cellular growth and metabolism in transformed cells.
-C-myc is a common oncogene that enhances aerobic glycolysis in the cancer cells by transcriptionally activating GLUT1, HK2, PKM2 and LDH-A

Inhibitors (downregulate):
Curcumin
Resveratrol: downregulate c-Myc expression.
Epigallocatechin Gallate (EGCG)
Quercetin
Berberine: decrease c-Myc expression and repress its transcriptional activity.
HCC, Hepatocellular Carcinoma: Click to Expand ⟱
Hepatocellular Carcinoma
Scientific Papers found: Click to Expand⟱
2606- Ba,    Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma
- Review, HCC, NA
ChemoSen↑, TumCP↓, TumCCA↑, TumCMig↓, TumCI↓, MMPs↓, MAPK↓, TGF-β↓, ZFX↓, p‑MEK↓, ERK↓, MMP2↓, MMP9↓, uPA↓, TIMP1↓, TIMP2↓, NF-kB↓, p65↓, p‑IKKα↓, Fas↑, Casp2↑, Casp3↑, Casp8↑, Casp9↑, Bcl-xL↓, BAX↑, ER Stress↑, Ca+2↑, JNK↑, P53↑, ROS↑, H2O2↑, cMyc↓, CD24↓, 12LOX↓,
2706- BBR,    Berberine Inhibits Growth of Liver Cancer Cells by Suppressing Glutamine Uptake
- in-vitro, HCC, Hep3B - in-vitro, HCC, Bel-7402 - in-vivo, NA, NA
TumCP↓, glut↓, SLC12A5↓, cMyc↓, GLS↓,
2421- PB,    Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c‐myc/hexokinase 2 pathway
- in-vitro, HCC, HCCLM3 - in-vivo, NA, NA - in-vitro, HCC, Bel-7402 - in-vitro, HCC, SMMC-7721 cell - in-vitro, Nor, L02
Glycolysis↓, Apoptosis↑, TumCP↓, lactateProd↓, GlucoseCon↓, HK2↓, ChemoSen↑, *toxicity↓, cMyc↓, PFK1↓, LDHA↓, cMyc↓, ChemoSen↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

H2O2↑, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

p‑MEK↓, 1,  

Core Metabolism/Glycolysis ⓘ

12LOX↓, 1,   cMyc↓, 4,   GLS↓, 1,   GlucoseCon↓, 1,   glut↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 1,   LDHA↓, 1,   PFK1↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-xL↓, 1,   Casp2↑, 1,   Casp3↑, 1,   Casp8↑, 1,   Casp9↑, 1,   Fas↑, 1,   JNK↑, 1,   MAPK↓, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CD24↓, 1,   ERK↓, 1,   ZFX↓, 1,  

Migration ⓘ

Ca+2↑, 1,   MMP2↓, 1,   MMP9↓, 1,   MMPs↓, 1,   TGF-β↓, 1,   TIMP1↓, 1,   TIMP2↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 3,   uPA↓, 1,  

Barriers & Transport ⓘ

SLC12A5↓, 1,  

Immune & Inflammatory Signaling ⓘ

p‑IKKα↓, 1,   NF-kB↓, 1,   p65↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 3,  
Total Targets: 45

Pathway results for Effect on Normal Cells:


Functional Outcomes ⓘ

toxicity↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: cMyc, cellular-MYC oncogene
1 Baicalein
1 Berberine
1 Phenylbutyrate
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:10  Cells:%  prod#:%  Target#:35  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page